Nucleocytoplasmic transport at the crossroads of proteostasis ... - John Wiley Sons
| MEDS Stock | 50.00 0.00 0.00% |
About 56% of PT Hetzer's investor base is looking to short. The analysis of current outlook of investing in PT Hetzer Medical suggests that many traders are alarmed regarding PT Hetzer's prospects. PT Hetzer's investing sentiment shows overall attitude of investors towards PT Hetzer Medical.
MEDS |
Nucleocytoplasmic transport at the crossroads of proteostasis ... John Wiley Sons
Read at news.google.com
 |
PT Hetzer Fundamental Analysis
We analyze PT Hetzer's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PT Hetzer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PT Hetzer based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
PT Hetzer is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
PT Hetzer Medical Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with PT Hetzer stock to make a market-neutral strategy. Peer analysis of PT Hetzer could also be used in its relative valuation, which is a method of valuing PT Hetzer by comparing valuation metrics with similar companies.
Peers
PT Hetzer Related Equities
| RAFI | PT Sari | 3.33 | ||||
| DEWI | PT Dewi | 1.20 | ||||
| KKES | PT Kusuma | 0.00 | ||||
| KRYA | Bangun Karya | 1.82 | ||||
| NICL | PAM Mineral | 3.27 |
Other Information on Investing in MEDS Stock
PT Hetzer financial ratios help investors to determine whether MEDS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in MEDS with respect to the benefits of owning PT Hetzer security.